Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35.

MacKenzie AE, Caltabiano G, Kent TC, Jenkins L, McCallum JE, Hudson BD, Nicklin SA, Fawcett L, Markwick R, Charlton SJ, Milligan G.

Mol Pharmacol. 2014 Jan;85(1):91-104. doi: 10.1124/mol.113.089482. Epub 2013 Oct 10.

2.

Antagonists of GPR35 display high species ortholog selectivity and varying modes of action.

Jenkins L, Harries N, Lappin JE, MacKenzie AE, Neetoo-Isseljee Z, Southern C, McIver EG, Nicklin SA, Taylor DL, Milligan G.

J Pharmacol Exp Ther. 2012 Dec;343(3):683-95. doi: 10.1124/jpet.112.198945. Epub 2012 Sep 11.

3.

G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium.

Yang Y, Lu JY, Wu X, Summer S, Whoriskey J, Saris C, Reagan JD.

Pharmacology. 2010;86(1):1-5. doi: 10.1159/000314164. Epub 2010 Jun 19.

PMID:
20559017
4.
5.

Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα₁₃ and β-arrestin-2.

Jenkins L, Alvarez-Curto E, Campbell K, de Munnik S, Canals M, Schlyer S, Milligan G.

Br J Pharmacol. 2011 Feb;162(3):733-48. doi: 10.1111/j.1476-5381.2010.01082.x.

6.

Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.

Jenkins L, Brea J, Smith NJ, Hudson BD, Reilly G, Bryant NJ, Castro M, Loza MI, Milligan G.

Biochem J. 2010 Dec 15;432(3):451-9. doi: 10.1042/BJ20101287.

PMID:
20919992
7.

High-throughput identification and characterization of novel, species-selective GPR35 agonists.

Neetoo-Isseljee Z, MacKenzie AE, Southern C, Jerman J, McIver EG, Harries N, Taylor DL, Milligan G.

J Pharmacol Exp Ther. 2013 Mar;344(3):568-78. doi: 10.1124/jpet.112.201798. Epub 2012 Dec 21.

8.

Protective effect of lodoxamide on hepatic steatosis through GPR35.

Nam SY, Park SJ, Im DS.

Cell Signal. 2019 Jan;53:190-200. doi: 10.1016/j.cellsig.2018.10.001. Epub 2018 Oct 7.

PMID:
30304698
9.

Crucial positively charged residues for ligand activation of the GPR35 receptor.

Zhao P, Lane TR, Gao HG, Hurst DP, Kotsikorou E, Le L, Brailoiu E, Reggio PH, Abood ME.

J Biol Chem. 2014 Feb 7;289(6):3625-38. doi: 10.1074/jbc.M113.508382. Epub 2013 Dec 17.

10.

[In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].

Blondin C, Cholley B, Haeffner-Cavaillon N, Goldschmidt P.

J Fr Ophtalmol. 2003 Apr;26(4):328-36. French.

11.

Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats.

Yanni JM, Weimer LK, Glaser RL, Lang LS, Robertson SM, Spellman JM.

Int Arch Allergy Immunol. 1993;101(1):102-6.

PMID:
7684628
12.

Inhibitory effects of lodoxamide on eosinophil activation.

Capron M, Loiseau S, Papin JP, Robertson S, Capron A.

Int Arch Allergy Immunol. 1998 Jun;116(2):140-6.

PMID:
9652307
13.
14.

Antiallergic activity of topical lodoxamide on in vivo and in vitro models.

Ciprandi G, Buscaglia S, Catrullo A, Paolieri F, Riccio AM, Fiorino N, Canonica GW.

Allergy. 1996 Dec;51(12):946-51.

PMID:
9020426
15.

Anti-inflammatory gallic Acid and wedelolactone are G protein-coupled receptor-35 agonists.

Deng H, Fang Y.

Pharmacology. 2012;89(3-4):211-9. doi: 10.1159/000337184. Epub 2012 Apr 4.

PMID:
22488351
16.

Orthologue selectivity and ligand bias: translating the pharmacology of GPR35.

Milligan G.

Trends Pharmacol Sci. 2011 May;32(5):317-25. doi: 10.1016/j.tips.2011.02.002. Epub 2011 Mar 9. Review.

PMID:
21392828
17.
18.

8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.

Funke M, Thimm D, Schiedel AC, Müller CE.

J Med Chem. 2013 Jun 27;56(12):5182-97. doi: 10.1021/jm400587g. Epub 2013 Jun 17.

PMID:
23713606
19.
20.

Lack of involvement of mast cell degranulation in the antiarrhythmic effect of preconditioning in rats.

Humphreys RA, Kane KA, Parratt JR.

J Cardiovasc Pharmacol. 1998 Mar;31(3):418-23.

PMID:
9514187

Supplemental Content

Support Center